Xeris Biopharma Holdings, Inc. (XERS) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Xeris Biopharma Holdings, Inc. (XERS) Bundle
Optimize your time and improve precision with our (XERS) DCF Calculator! Equipped with up-to-date data on Xeris Biopharma Holdings, Inc. and customizable assumptions, this tool enables you to forecast, analyze, and evaluate (XERS) just like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.2 | 49.6 | 110.2 | 110.2 | 163.9 | 265.8 | 431.1 | 699.1 | 1,133.7 | 1,838.5 |
| Revenue Growth, % | 0 | 146.04 | 122.32 | 0 | 48.68 | 62.17 | 62.17 | 62.17 | 62.17 | 62.17 |
| EBITDA | -117.8 | -80.1 | -113.7 | -69.3 | -23.7 | -200.6 | -325.3 | -527.6 | -855.6 | -1,387.5 |
| EBITDA, % | -584.46 | -161.48 | -103.1 | -62.87 | -14.48 | -75.47 | -75.47 | -75.47 | -75.47 | -75.47 |
| Depreciation | 1.1 | 1.5 | 1.9 | 12.7 | 13.2 | 15.7 | 25.5 | 41.3 | 67.0 | 108.6 |
| Depreciation, % | 5.35 | 2.96 | 1.7 | 11.49 | 8.03 | 5.91 | 5.91 | 5.91 | 5.91 | 5.91 |
| EBIT | -118.9 | -81.5 | -115.5 | -82.0 | -36.9 | -211.0 | -342.2 | -554.9 | -899.8 | -1,459.3 |
| EBIT, % | -589.8 | -164.44 | -104.8 | -74.36 | -22.51 | -79.37 | -79.37 | -79.37 | -79.37 | -79.37 |
| Total Cash | 133.8 | 102.4 | 122.0 | 122.0 | 72.5 | 236.2 | 383.0 | 621.1 | 1,007.2 | 1,633.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4.7 | 6.9 | 17.5 | 30.8 | 39.2 | 55.7 | 90.4 | 146.6 | 237.8 | 385.6 |
| Account Receivables, % | 23.28 | 13.86 | 15.83 | 27.96 | 23.91 | 20.97 | 20.97 | 20.97 | 20.97 | 20.97 |
| Inventories | 8.4 | 18.1 | 24.7 | 24.7 | 38.8 | 77.9 | 126.3 | 204.9 | 332.3 | 538.8 |
| Inventories, % | 41.44 | 36.54 | 22.44 | 22.44 | 23.69 | 29.31 | 29.31 | 29.31 | 29.31 | 29.31 |
| Accounts Payable | 5.6 | 3.1 | 8.9 | 4.6 | 11.6 | 28.4 | 46.1 | 74.7 | 121.1 | 196.4 |
| Accounts Payable, % | 27.8 | 6.29 | 8.09 | 4.18 | 7.06 | 10.68 | 10.68 | 10.68 | 10.68 | 10.68 |
| Capital Expenditure | -.4 | -1.1 | -.5 | -.5 | -2.3 | -3.4 | -5.5 | -8.9 | -14.5 | -23.5 |
| Capital Expenditure, % | -1.87 | -2.19 | -0.47529 | -0.47529 | -1.38 | -1.28 | -1.28 | -1.28 | -1.28 | -1.28 |
| Tax Rate, % | 1.97 | 1.97 | 1.97 | 1.97 | 1.97 | 1.97 | 1.97 | 1.97 | 1.97 | 1.97 |
| EBITAT | -118.7 | -81.5 | -113.8 | -80.8 | -36.2 | -208.9 | -338.7 | -549.3 | -890.8 | -1,444.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -125.5 | -95.6 | -123.9 | -86.3 | -40.8 | -235.3 | -384.2 | -623.0 | -1,010.4 | -1,638.5 |
| WACC, % | 10.87 | 10.87 | 10.82 | 10.82 | 10.8 | 10.83 | 10.83 | 10.83 | 10.83 | 10.83 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2,631.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,671 | |||||||||
| Terminal Value | -18,918 | |||||||||
| Present Terminal Value | -11,311 | |||||||||
| Enterprise Value | -13,943 | |||||||||
| Net Debt | 162 | |||||||||
| Equity Value | -14,104 | |||||||||
| Diluted Shares Outstanding, MM | 138 | |||||||||
| Equity Value Per Share | -102.45 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real XERS financials.
- Real-World Data: Access to historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Modify forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe how your inputs affect Xeris Biopharma's valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Financial Data: Gain access to reliable pre-loaded historical performance metrics and future forecasts for Xeris Biopharma Holdings, Inc. (XERS).
- Adjustable Forecast Inputs: Modify highlighted cells for assumptions such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Enjoy automatic recalculations for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: View clear charts and summaries to easily interpret your valuation outcomes.
- Designed for All Skill Levels: An intuitive layout tailored for investors, financial officers, and consultants alike.
How It Works
- Download: Obtain the pre-built Excel file containing Xeris Biopharma Holdings, Inc. (XERS) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC as needed.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time for accuracy.
- Test Scenarios: Develop various projections and evaluate results instantly.
- Make Decisions: Leverage the valuation outcomes to inform your investment approach.
Why Choose This Calculator for Xeris Biopharma Holdings, Inc. (XERS)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Easily adjust parameters to suit your financial analysis.
- Real-Time Feedback: Observe immediate changes to Xeris's valuation as you modify inputs.
- Pre-Loaded Data: Comes with Xeris's actual financial metrics for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for analyzing portfolios involving Xeris Biopharma Holdings, Inc. (XERS).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Xeris Biopharma Holdings, Inc. (XERS).
- Students and Educators: Utilize real-time data to enhance learning and practice in financial modeling related to biopharmaceuticals.
- Healthcare Investors: Gain insights into how biopharma companies like Xeris Biopharma Holdings, Inc. (XERS) are assessed in the market.
What the Template Contains
- Preloaded XERS Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.